President & CEOOfficers of the CorporationBoard of TrusteesFoundation BoardLeadership CouncilAbout Joslin ResearchAdvocacy & Gov't AffairsHistory
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Make an AppointmentAdult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAfrican American ProgramsAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingHealthcare ProfessionalsCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Psychoses, Bipolar Disorders, and Cardiometabolic Risk: Office Systems for Assessment and Treatment

Activity Description

Psychoses, Bipolar Disorders, and Cardiometabolic Risk: Office Systems for Assessment and Treatment

New York, New York
Tuesday, February 12, 2013
6:00 PM - 8:45 PM
Statement of Need

People with psychiatric and mood disorders are at increased risk for metabolic syndrome, a constellation of several comorbid risk factors for cardiovascular disease including obesity, hyperlipidemia, hypertension, and impaired glucose tolerance. Because second-generation antipsychotics can increase cardiometabolic risk, mental health professionals need to strike a balance between psychiatric improvement and metabolic impairment in their patients with schizophrenia or bipolar or other mood disorders.

This symposium will help you achieve this balance by teaching you how to effectively screen patients for cardiometabolic risk factors and monitor patients on antipsychotics for increased risk, as well as how your clinical and office staff can help you identify patients at risk. You will also learn about effective interventions to limit metabolic risk among people with psychotic disorders and how to office systems can help you efficiently prevent, identify, and treat cardiometabolic risk factors or coordinate such care with your patients medical providers.

Target Audience

This certified live activity has been developed for mental health professionals. There is no fee to attend this live activity. However, space is limited, and reservations will be accepted on a first-come, first-served basis. Only clinicians can be admitted. Guests who are not clinicians cannot be accommodated.

Topics
5:30 PM Registration and Dinner
6:00 Opening Remarks and Introduction of ARS and Case Vignettes
6:10 Cardiometabolic Risk: Identification and Intervention
6:40 The Psychiatric Issues: Balancing Antipsychotic Efficacy With Metabolic Control
7:10 Discussion of 2 Clinical Case Vignettes
8:30 Question and Answer Session
8:45 Concluding Remarks and Adjournment
Learning Objectives

Participants will be provided with clinically relevant, evidence-based information.
Upon completion of this activity, participants should be able to:

  • Describe the cardiometabolic risk factors that compose the cardiometabolic syndrome and other key markers of increased cardiovascular risk
  • Identify specific components of the cardiometabolic syndrome in people with schizophrenia, bipolar, and other mood disorders that require medical intervention
  • Design, implement, and manage optimally effective antipsychotic drug interventions using second-generation antipsychotic medications to achieve optimal balance between needed antipsychotic and other targeted effects and the potential for metabolic derangements
  • Develop office-based systems to effectively assess the metabolic status and/or presence of key cardiometabolic risk factors for people with schizophrenia and other psychoses, particularly those starting on, or currently treated with, second-generation (“atypical”) antipsychotic medications
  • Develop office-based systems to ensure that people with schizophrenia and other psychoses who are at increased cardiometabolic risk receive effective interventions, either directly or through consultative assistance, to reduce that risk and blunt the impact on vascular health

This activity has been designed to address and encourage the following IOM/ACGME Competencies:

  • Medical knowledge
  • Professionalism
  • Evidence-based practice
Faculty

Speakers for this activity will be drawn from the distinguished faculty listed below.*

Richard S. Beaser, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Medical Executive Director
Professional Education
Joslin Diabetes Center
Boston, MA

Seth Braunstein, MD, PhD
Associate Professor of Medicine
Diabetes Program
University of Pennsylvania School of Medicine
Philadelphia, PA

Philip Levy, MD, MACE
Clinical Professor of Medicine
University of Arizona College of Medicine
Phoenix, AZ

Theo C. Manschreck, MD, MPH
Professor of Psychiatry
Harvard Medical School
Senior Psychiatrist
Massachusetts General Hospital
Boston, MA
Medical and Research Director
JC Corrigan Mental Health Center
Fall River, MA
Psychiatry Service
Brockton VA Medical Center
Brockton, MA

*Faculty list subject to change

Accreditation and Designation of Credit

Joslin Diabetes Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Joslin Diabetes Center designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME live activity was planned and produced in accordance with ACCME Essentials. Health professionals not eligible for continuing medical education credit will receive a certificate of participation that they may submit to their state licensing board for credit.

Disclosure Policy

It is the policy of Joslin Diabetes Center to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by Joslin Diabetes Center are required to present evidence-based data, identify and reference off-label product use, and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This activity is supported by educational grants from Janssen Medical Affairs LLC, and Otsuka America Pharmaceutical, Inc.

Page last updated: August 29, 2014